Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 220
- Registration Number
- NCT00266253
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)Drug: Placebo
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 267
- Registration Number
- NCT00266240
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT00233883
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 361
- Registration Number
- NCT00232908
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT00231478
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 896
- Registration Number
- NCT00192647
A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00148915
- Locations
- 🇺🇸
GSK Investigational Site, Duncansville, Pennsylvania, United States
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Phase 4
Completed
- Conditions
- Post-Menopausal Osteopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT00129623
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Phase 4
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2011-08-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 157
- Registration Number
- NCT00127933
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT00121784
© Copyright 2025. All Rights Reserved by MedPath